SCPH scPharmaceuticals Inc.

5.82
-0.24  -4%
Previous Close 6.06
Open 6.1
Price To Book 1.87
Market Cap 108,141,013
Shares 18,580,930
Volume 34,282
Short Ratio
Av. Daily Volume 50,226
Stock charts supplied by TradingView

NewsSee all news

  1. scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce

  2. scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference

    BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of

  3. scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies Completed $20.0

  4. scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement

    Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank BURLINGTON, Mass.,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 planned.
scCeftriaxone
Infections caused by gram-positive and gram-negative organisms
CRL issued June 13, 2018. NDA to be refiled mid-2020.
Furoscix
Heart failure
NDA filing due 2021.
Ceftriaxone
Baceteria infections

Latest News

  1. scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce

  2. scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference

    BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of

  3. scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies Completed $20.0

  4. scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement

    Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank BURLINGTON, Mass.,